Evaluation de la tolérance à la protéine HIP/PAP dans le cadre d'un essai clinique de phase I chez des patients atteints d'hépatite aiguë. Prévention de la progression vers l'hépatite fulminante – HIP in Hepatitis

Paul AMOUYAL (PME (petite et moyenne entreprise))

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Help of the ANR 934,005 euros
Beginning and duration of the scientific project: - 36 Months

• List of selected projects
• Permanent link to this summary on the ANR website (ANR-07-PRIB-0008)
• See the publications in the HAL-ANR portal